Treace to Report First Quarter 2025 Financial Results on May 8, 2025
Treace Medical Concepts (TMCI), a medical technology company specializing in bunion and midfoot deformity surgical treatments through its Lapiplasty® and Adductoplasty® Procedures, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close.
The company will host a conference call at 4:30 pm ET to discuss the results. Interested investors can participate by registering to receive dial-in numbers and a unique pin. A live and archived webcast will be available on the company's investor relations website at https://investors.treace.com/.
Treace Medical Concepts (TMCI), un'azienda di tecnologia medica specializzata nei trattamenti chirurgici per alluce valgo e deformità del mesopiede tramite le procedure Lapiplasty® e Adductoplasty®, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per il 8 maggio 2025, dopo la chiusura dei mercati.
L'azienda terrà una conference call alle 16:30 ET per discutere i risultati. Gli investitori interessati possono partecipare registrandosi per ricevere i numeri di accesso e un pin univoco. Una webcast in diretta e registrata sarà disponibile sul sito web delle relazioni con gli investitori all'indirizzo https://investors.treace.com/.
Treace Medical Concepts (TMCI), una empresa de tecnología médica especializada en tratamientos quirúrgicos para juanetes y deformidades del mediopié mediante sus procedimientos Lapiplasty® y Adductoplasty®, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el 8 de mayo de 2025, después del cierre del mercado.
La compañía realizará una llamada conferencia a las 4:30 pm ET para discutir los resultados. Los inversores interesados pueden participar registrándose para recibir los números de acceso y un PIN único. Una transmisión en vivo y archivada estará disponible en el sitio web de relaciones con inversionistas de la compañía en https://investors.treace.com/.
트레이스 메디컬 콘셉트(TMCI)는 Lapiplasty® 및 Adductoplasty® 시술을 통한 무지외반증 및 중족부 변형 수술 치료를 전문으로 하는 의료기술 회사로, 2025년 1분기 재무 실적 발표를 2025년 5월 8일 장 마감 후에 예정하고 있습니다.
회사는 결과를 논의하기 위해 동부 표준시 오후 4시 30분에 컨퍼런스 콜을 진행할 예정입니다. 관심 있는 투자자는 등록하여 전화 접속 번호와 고유 PIN을 받을 수 있습니다. 생중계 및 녹화된 웹캐스트는 회사의 투자자 관계 웹사이트 https://investors.treace.com/에서 이용 가능합니다.
Treace Medical Concepts (TMCI), une entreprise de technologie médicale spécialisée dans les traitements chirurgicaux des oignons et des déformations du médio-pied via ses procédures Lapiplasty® et Adductoplasty®, a prévu d'annoncer ses résultats financiers du premier trimestre 2025 le 8 mai 2025, après la clôture des marchés.
L'entreprise tiendra une conférence téléphonique à 16h30 ET pour discuter des résultats. Les investisseurs intéressés peuvent s'inscrire pour recevoir les numéros d'appel et un code PIN unique. Une diffusion en direct et une rediffusion seront disponibles sur le site des relations investisseurs de l'entreprise à l'adresse https://investors.treace.com/.
Treace Medical Concepts (TMCI), ein Medizintechnikunternehmen, das sich auf chirurgische Behandlungen von Ballenzehen und Mittelfußdeformitäten durch seine Lapiplasty®- und Adductoplasty®-Verfahren spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für den 8. Mai 2025 nach Börsenschluss geplant.
Das Unternehmen wird um 16:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Interessierte Investoren können sich registrieren, um Einwahlnummern und eine individuelle PIN zu erhalten. Ein Live- und ein archiviertes Webcast werden auf der Investor-Relations-Website des Unternehmens unter https://investors.treace.com/ verfügbar sein.
- None.
- None.
PONTE VEDRA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the first quarter 2025 after the close of trading on Thursday, May 8, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET.
Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and archived webcast of the event will be available on the Company’s investor relations website at https://investors.treace.com/.
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP™ Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty™ 3D Minimally Invasive Bunion Correction System and the Percuplasty™ Percutaneous 3D Bunion Correction System. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty® and Adductoplasty® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com.
To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
Investors:
Gilmartin Group
Philip Trip Taylor
IR@treace.net
FAQ
When will Treace Medical (TMCI) release Q1 2025 earnings?
How can investors join TMCI's Q1 2025 earnings call?
Where can I find TMCI's Q1 2025 earnings webcast?
What are Treace Medical's main surgical products?
